Intracranial Pressure Is a Determinant of Sympathetic Activity

Eric A. Schmidt¹,², Fabien Despas¹,³, Anne Pavy-Le Traon¹,⁴, Zofia Czosnyka⁵, John D. Pickard⁵, Kamal Rahmouni⁶, Atul Pathak¹,³ and Jean M. Senard¹,³

¹ Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Institut National de la Santé et de la Recherche Médicale, Université de Toulouse, Toulouse, France, ² Department of Neurosurgery, University Hospital of Toulouse, Toulouse, France, ³ Department of Clinical Pharmacology, University Hospital of Toulouse, Toulouse, France, ⁴ Department of Neurology, University Hospital of Toulouse, Toulouse, France, ⁵ Brain Physics Lab, Academic Neurosurgery, University of Cambridge, Cambridge, United Kingdom, ⁶ Departments of Pharmacology, University of Iowa, Iowa City, IA, United States

Intracranial pressure (ICP) is the pressure within the cranium. ICP rise compresses brain vessels and reduces cerebral blood delivery. Massive ICP rise leads to cerebral ischemia, but it is also known to produce hypertension, bradycardia and respiratory irregularities due to a sympatho-adrenal mechanism termed Cushing response. One still unresolved question is whether the Cushing response is a non-synaptic acute brainstem ischemic mechanism or part of a larger physiological reflex for arterial blood pressure control and homeostasis regulation. We hypothesize that changes in ICP modulate sympathetic activity. Thus, modest ICP increase and decrease were achieved in mice and patients with respectively intra-ventricular and lumbar fluid infusion. Sympathetic activity was gauged directly by microneurography, recording renal sympathetic nerve activity in mice and muscle sympathetic nerve activity in patients, and gauged indirectly in both species by heart-rate variability analysis. In mice (n = 15), renal sympathetic activity increased from 29.9 ± 4.0 bursts.s⁻¹ (baseline ICP 6.6 ± 0.7 mmHg) to 45.7 ± 6.4 bursts.s⁻¹ (plateau ICP 38.6 ± 1.0 mmHg) and decreased to 34.8 ± 5.6 bursts.s⁻¹ (post-infusion ICP 9.1 ± 0.8 mmHg). In patients (n = 10), muscle sympathetic activity increased from 51.2 ± 2.5 bursts.min⁻¹ (baseline ICP 8.3 ± 1.0 mmHg) to 66.7 ± 2.9 bursts.min⁻¹ (plateau ICP 25 ± 0.3 mmHg) and decreased to 58.8 ± 2.6 bursts.min⁻¹ (post-infusion ICP 14.8 ± 0.9 mmHg). In patients 7 mmHg ICP rise significantly increases sympathetic activity by 17%. Heart-rate variability analysis demonstrated a significant vagal withdrawal during the ICP rise, in accordance with the microneurography findings. Mice and human results are alike. We demonstrate in animal and human that ICP is a reversible determinant of efferent sympathetic outflow, even at relatively low ICP levels. ICP is a biophysical stress related to the forces within the brain. But ICP has also to be considered as a physiological stressor, driving sympathetic activity. The results suggest a novel physiological ICP-mediated sympathetic modulation circuit and the existence of a possible intracranial (i.e., central) baroreflex. Modest ICP rise might participate to the pathophysiology of cardiac-metabolic homeostasis imbalance with sympathetic over-activity, and to the pathogenesis of sympathetically-driven diseases.

Keywords: intracranial pressure, autonomic nervous system, baroreflex, microneurography, translational medical research, physiology
INTRODUCTION

Intracranial pressure (ICP) is a complex brain modality that determines cerebral perfusion pressure (CPP), which is the difference between arterial blood pressure (ABP), and ICP. Raised ICP reduces CPP and blood delivery to the brain that jeopardizes cerebral function and organismal survival in many species. A massive rise in ICP is also known to produce an increase in ABP, bradycardia and respiratory irregularities termed Cushing response (Cushing, 1901). This mechanism is generally considered to be an agonal and terminal event occurring in extreme condition of brainstem ischaemia leading to a sympatho-adrenal response (McGillicuddy et al., 1978; Nagao et al., 1984; Van Loon et al., 1993). However, it is still debated whether the Cushing response is an acute pathological response to brain ischemia or part of an important physiological reflex mechanism for ABP regulation (Paton et al., 2009). This assumption is based on the following findings: (i) experimental studies show that ABP is sensitive to small changes in ICP in dogs (Jeffers et al., 1937; Dickinson and McCubbin, 1963), cats (Nakamura et al., 1987), and rabbits (Edvinsson et al., 1971; Donnelly et al., 2017), (ii) demonstration in non-human primates of a short lasting, repeatable and non-terminal vasomotor response to modest ICP increase (Fitch et al., 1977), (iii) presence of pressure receptive area located in the lower brainstem (Thompson and Malina, 1959; Hoff and Reis, 1970; Doba and Reis, 1972; Reis and Doba, 1972), (iv) bedside evidence that modest and controlled ICP rise in non-lethal conditions might yield a concomitant and reversible rise in ABP (Dickinson, 1981), (v) modest and gradual ICP rise in awake patients produces an increase in ABP and heart rate (HR) variance (Schmidt et al., 2005), (vi) demonstration of an interdependency between ICP and HR variability suggesting a centrally organized neural control (Hu et al., 2007), (vii) ICP rise augments ICP variability and reduces ICP complexity (Santamarta et al., 2012), and finally (viii) the suggested ability of the central nervous system to modulate the set point of the arterial baroreceptor reflex (Osborn, 2005). Hence, animal and clinical studies suggest that ICP change may modulate systemic hemodynamics probably via the sympathetic nervous system (SNS). But direct demonstration that ICP modulates SNS is still lacking.

In the present study, we hypothesize that modest ICP changes drive sympathetic activity. Using microneurography, state-of-the-art technique to measure in vivo direct and dynamic post-ganglionic SNS activity, we performed two different sets of experiments in mice and patients. During controlled modest ICP increase and decrease, sympathetic activity was measured directly by renal sympathetic nerve activity (RSNA) in mice and by muscle sympathetic nerve activity (MSNA) in patients. SNS activity was also indirectly gauged by HR variability analysis in animal and human.

METHODS

Animal Experiments

All studies were approved by the University of Iowa Animal Research Committee. Experiments were performed in adult male mice (C57BL/6j; Jackson Laboratory, USA). Experiments were performed by trained and authorized staff (KR, FD). Mice were anesthetized and placed in a stereotactic device (Kopf Instruments). A sterile cerebro-ventricular cannula was implanted into the right lateral ventricle and sealed on the skull with dental cement. This cannulation was used to infuse fluid in the ventricle to increase ICP. Mice were given 5–7 days to recover from ventricular cannulation before the experimental procedure.

ICP Increase in Animal

Mice were anesthetized by i.p. injection of ketamine (91 mg.kg⁻¹) plus xylazine (9.1 mg.kg⁻¹) and intubated (PE-50) to allow spontaneous respiration of oxygen-enriched room air. Body temperature was kept constant at 37.5°C using a surgical heat lamp and a heat pad. The right jugular vein was cannulated to maintain anesthesia with α-chloralose (initial dose 25 mg.kg⁻¹, sustaining dose of 6 mg.kg⁻¹.h⁻¹). This standard anesthetic protocol has little impact on SNS activity and was shown to be adapted to RNSA recording (Rahmouni et al., 2005). The skull of the mouse was perforated in the left frontal region and a pressure sensor (CODMAN, USA) was inserted 0.5 cm deep within the brain and sealed with dental cement. The cerebro-ventricular cannula were connected to a 1 ml syringe with a micro-renathane tubing (Braintree Scientific, Braintree, MA, USA) filled with artificial cerebrospinal fluid (CSF). Temperature of the artificial CSF was controlled by immersion of the tubing in a water container at 37.5°C. The artificial CSF was injected with a controlled micro-debit pump at a rate from 5 to 50 μl.min⁻¹ (Syringe pumps for mass spectrometry, Harvard Apparatus, Holliston, Massachusetts, USA). ICP was recorded at baseline for 10 min; then the ventricle was infused with artificial CSF at body temperature with a constant rate.

Arterial Blood Pressure, Respiratory, and Sympathetic Recording in Animal

Physiological parameters were continuously monitored. ABP and HR were measured from a femoral arterial line (AD Instruments, Castle Hill, Australia). Respiratory movements were measured with a piezoelectric sensor placed on rib cage (AD Instruments, Castle Hill, New South Wales, Australia). After a left lumbar dissection, the kidney was exposed via a retroperitoneal approach. A 36-gauge platinum–iridium bipolar electrode (Cooner Wire Co, Chadsworth, California, USA) placed on the nerves of the left kidney in order to record RSNA. The procedure is detailed by Rahmouni et al. (2005). Once optimal recording parameters were established, the nerve fibers were fixed to the electrodes with silicone gel activity; SNS, sympathetic nervous system; TP, total power of heart rate variability analysis.

Abbreviations: ABP, arterial blood pressure; CPP, cerebral perfusion pressure; CSF, cerebrospinal fluid; FFT, fast Fourier transform; HB, heart beats; HF, high frequency of heart rate variability analysis; HR, heart rate; ICP, intracranial pressure; LF, low frequency of heart rate variability analysis; MSNA, muscle sympathetic nerve activity; PI, pulse interval; RSNA, renal sympathetic nerve activity; SNS, sympathetic nervous system; TP, total power of heart rate variability analysis.
Schmidt et al. Intracranial Baroreflex (Kwik-Sil, World Precision Instruments Inc, Sarasota, Florida, USA). The nerve electrodes were attached to a high-impedance probe (HIP-511, Grass Instruments Co, Quincy, Massachusetts, USA). The signal was amplified 10^5 times with a Grass P5 AC preamplifier and filtered at both low (100 Hz) and high-frequency (1,000 Hz) cut-off. The signal was also routed to a Powerlab analog–digital converter (Ad Instruments, Castle Hill, Australia) for recording and off-line data analysis on a computer. The signal was amplified, filtered, rectified, integrated and RSNA was expressed in bursts s^{-1} (Rahmouni et al., 2005). At the end of the study, mice were euthanized with a lethal dose of ketamine and xylazine. The integrated voltage after death (background noise) was subtracted from the total integrated voltage to calculate real RSNA.

In a preliminary study (n = 4), a massive ICP rise was performed. ICP was slowly increased to reach diastolic ABP in order to validate that our animal model elicits a Cushing response and to define the upper ICP threshold that do not produce any significant ABP increase (cf. Figures 1A–C). ICP over 50 mmHg yields a Cushing response with systolic and diastolic ABP increase (cf. Figures 1A,B), steep augmentation of RSNA due to massive SNS activation (cf. Figure 1C) and respiratory arrest leading to a quick death. Therefore, the upper ICP threshold for our mice study was set at 40 mmHg.

For the animal experiments (n = 15) a 10-min baseline period was recorded, then ICP was slowly increased up to 40 mmHg. Once this upper ICP threshold has been reached, the artificial CSF infusion was stopped and ICP slowly decreased to a steady post-infusion pressure.

Off-line, dynamic changes of RSNA were measured during 60 s epochs at baseline ICP and at various ICP levels: 10, 20, 30, and 40 mmHg. RSNA was also measured after the end of the infusion when ICP reached a steady post-infusion level.

Heart Rate Variability Analysis in Animal
The ABP signal was digitized at 1,000 Hz and processed (Labchart 5.0, AD Instruments, Castle Hill, Australia). Pulse interval (PI, surrogate for R-R interval) was calculated between two successive dABP/dt max points. Each recording was visualized to select one period without erratic fluctuations of enough duration (>51.2 s) for each session. The rhythmicity of PI was evaluated by power spectral analysis using a fast Fourier transform (FFT) (HR variability analysis, AD Instruments, Castle Hill, New South Wales, Australia). Briefly, the evenly spaced sampling allowed for direct spectral analysis using a FFT algorithm of a 1,024 point series, corresponding to a 51.2 s period, using a sampling rate of 20 Hz. Two bands of FFT the spectrum were considered. The first zone covers the 0.15–0.60 Hz range of the PI spectrum and corresponds to the LF zone. The second zone covers the 2.5–5.0 Hz range of the PI spectrum and corresponds to the HF zone. HF is a reasonable index of parasympathetic activity whereas LF and LF/HF are supposed to be related to sympathetic activity (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996). In our study, HR variability results were safely interpreted as an indication of vagal withdrawal (HF) (Marchi et al., 2016a).

FIGURE 1 | (A) Animal results for massive ICP increase (n = 4). Individual animal results of systolic ABP (A), diastolic ABP (B), and RSNA (C) during massive ICP increase. The Cushing response was elicited at ICP 50 mmHg, with an increase in ABP (cf. A,B) and a steep augmentation of RSNA due to massive SNS activation (cf. C) leading to respiratory arrest and to a quick death. For our proper study, the upper ICP threshold was set at 40 mmHg, before the onset of the Cushing response. No statistical analysis has been performed.

One mouse was excluded from the analysis due to heart rate disorders.

Human Experiments
The study was approved by the competent authority and registered by ClinicalTrials.gov under n° NCT01776801. Ten patients suspected of normal pressure hydrocephalus (sex ratio 7/3, mean age 65.2 ± 4.6 years, mean body mass index 25.6 ± 1.2 kg.m^−2) were included in this prospective study after they gave their informed and written consent. The experiment was performed in the autonomic unit at Toulouse University Hospital by trained staff (AP, FD).
ICP Increase in Human
Lumbar infusion studies are procedures performed in awake patients to assess CSF hydrodynamics. This procedure is painless (Manet et al., 2016) and recommended by experts (Marmarou et al., 2005) as part of the clinical management of patients with possible normal pressure hydrocephalus. The patient was lying horizontally, in left lateral recumbent. A lumbar puncture (L4-L5 or L5-S1) was performed with a 19G needle. Then the needle was connected, via a 3 way tap and a stiff tube filled with normal saline, to an infusion pump and a pressure transducer. CSF pressure, once zeroed at the level of the third ventricle, is a surrogate marker of ICP (Lenfeldt et al., 2007). CSF pressure was digitized and stored in a computer for offline analysis. ICP was measured at baseline for 10 min. Then the lumbar subarachnoid space was slowly infused with normal saline solution (0.9%) at room temperature (20°C) at a rate of 1.5 ml.min⁻¹. Subsequently ICP increased until a steady-state plateau has been reached. This plateau ICP represents the equilibrium at which the mock CSF infusion flow is reabsorbed through the arachnoid granulations into the venous blood stream. For safety reasons, ICP was always kept below 40 mmHg. Once the plateau ICP has been achieved, the saline infusion was stopped and ICP slowly decreased to a steady post-infusion pressure.

Arterial Blood Pressure, Respiratory, and Sympathetic Recording in Human
Physiological parameters were continuously monitored. HR was measured by EKG (AD Instruments, Castle Hill, Australia), ABP using photoplethysmography (Finapres Medical System BV, Amsterdam, The Netherlands), oxygen saturation with a pulse oximeter (AD Instruments, Castle Hill, New South Wales, Australia) and respiratory movement with a thoracic belt (Pneumotrace II, UFI, California, USA).

Muscle sympathetic nerve activity (MSNA) was measured in patients during the infusion test under carefully standardized conditions (White et al., 2015). Signal was recorded by a sterile single-use tungsten microelectrode (shaft diameter, 200 μm) inserted selectively in sympathetic efferent fibers around the right fibular nerve. A subcutaneous reference electrode was inserted 2–3 cm away from the recording microelectrode. Electrode was manipulated until a satisfactory signal was recorded. Once positioned, the recording microelectrode allows the collection of the electrical activity of sympathetic contingent, which appears as a sequence of electrical bursts. In the absence of sensory stimuli and muscle movement, the potential difference measured between the 2 microelectrodes is the sum of the electrical activity of sympathetic fibers of the peripheral muscle vessels. To validate the correct positioning of the microelectrode recording, two tests were carried out: cutaneous stimulation and apnoea. Cutaneous stimulation of the fibular nerve distribution territory should not cause changes in the neurogram activity. Voluntary apnoea and expiration was performed by the subject to activate SNS and should produce an increase in the frequency and amplitude of measured bursts. These tests were done before and after the infusion to verify the correct positioning of the microelectrode. The neural signal was amplified, filtered, rectified and integrated to obtain a neurogram identifying trains of SNS discharge visualized as a sequence of bursts. MSNA was expressed both in bursts.min⁻¹ and bursts/100 heart beats (HB).

Off-line, dynamic changes of sympathetic nerve activity were measured during 60 s epochs at baseline ICP and at various ICP levels: 10, 15, 20, and 25 mmHg. MSNA activity was also measured 5 min after the end of infusion when ICP reached a steady post-infusion level.

Heart Rate Variability Analysis in Human
RR intervals derived from EKG were digitized. Series of 512 equidistant values were sampled at 2 Hz, generated and stored in a computer for off-line analysis. Spectral analysis was performed using a FFT algorithm (HR variability analysis, AD Instruments, Castle Hill, Australia) at baseline and during the ICP plateau. Each recording was examined to verify stationarity of the signal using autoregression coefficient monitoring and elimination of artifacts. In accordance with current guidelines for HR variability analysis, the integration of the spectral modulus values from 0.004 to 1 Hz was used to estimate the total power (TP). The integration of the spectral energy contained in consecutive bands between 0.04 and 0.15 Hz from HR spectrum was used to measure low-frequency (LF) band. The integration of spectral energy contained between 0.15 and 0.40 Hz from HR spectrum has been used to measure high frequency (HF) band. With the limits mentioned in the mice section, the relative energy in HF band (nu) of HR spectrum [(HF spectral modulus/TP spectral modulus) * 100] was used as an index of parasympathetic activity. LF expressed in normalized units [(LF spectral modulus/TS spectral modulus)*100] and the ratio between LF/HF are supposed to be related to sympathetic activity (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996). In our study, HR variability results were safely interpreted as an indication of vagal withdrawal (HF) (Marchi et al., 2016a).

Statistics
This study was designed to test the effect of ICP on SNS activity in mice and human. Analyses of animal and clinical data were carried out off line by two different investigators and values were averaged for each period. The first analysis was performed by one of the investigator (FD); the second analysis was done by a research assistant. Both investigators were blind from the ICP changes.

Data are expressed as mean ± standard error of the mean (sem). Equality of variance was performed with Bartlett’s test. Parametric analyses were performed with repeated measures ANOVA with Tukey’s post-test, and non-parametric analyses were performed with a Friedman test with Dunns’ post-test. All testing was two-sided and a p < 0.05 was considered to indicate statistical significance. All analyses were completed with Graphpad Prism, version 5.04 for PC.
RESULTS

Effect of Modest ICP Increase on Sympathetic Activity in Animal

Figure 2 is an example of a mouse recording with raw signals of ICP, respiration, ABP and RSNA. Figure 3 displays individual RSNA results in each mouse during modest ICP increase and decrease. Figure 4 is a graph of RSNA vs. ICP. Table 1 shows animal results (RSNA, systolic and diastolic ABP, HR, respiratory rate and amplitude) during modest ICP increase and decrease. Table 2 depicts the results of spectral analysis of HR variability at baseline and plateau ICP in mice. Statistical significance is indicated in Figures 3, 4 and Tables 1, 2.

In animal, a modest rise in ICP provoked a significant augmentation in RSNA (cf. Table 1, Figures 3, 4). The increase in ICP and RSNA were parallel. At the end of infusion, the drop in ICP was associated with a significant reduction in RSNA reflecting partial reversibility of the ICP-mediated sympathetic activation (cf. Table 1, Figures 3, 4). During the ICP rise, ABP remained stable and no change in HR was noticed (cf. Table 1). Respiratory rate was unchanged but respiratory amplitude augmented significantly during the ICP rise (cf. Table 1). Spectral analysis of HR variability (cf. Table 2) showed that the rise in ICP was significantly associated with a decrease in HF power (parasympathetic index), whereas LF power and LF/HF ratio increased. This pattern of vagal withdrawal is in accordance with the RSNA results. In mice a modest ICP increase augments pari passu efferent SNS outflow, and an ICP drop reduces SNS outflow.

Effect of Modest ICP Increase on Sympathetic Activity in Human

Figure 5 is an example of a patient recording with raw signals of ICP, respiration, ABP and MSNA. Figure 6 displays individual MSNA results in each patient during modest ICP increase and decrease. Figure 7 is a graph of MSNA vs. ICP. Table 3 shows human results (MSNA, systolic and diastolic ABP, HR, oxygen saturation, respiratory rate and amplitude) during modest ICP increase and decrease. Table 4 depicts the results of spectral analysis of HR variability at baseline and plateau ICP in patients. Statistical significance is indicated in Figures 6, 7 and Tables 3, 4.

In human, a modest rise in ICP provoked a significant augmentation in MSNA (cf. Table 3, Figures 6, 7). The increase in ICP and MSNA were parallel. At the end of infusion, the drop in ICP was associated with a significant reduction in MSNA reflecting partial reversibility of the ICP-mediated sympathetic activation (cf. Table 3, Figures 6, 7). During the ICP rise, ABP remained stable and no change in HR or oxygen saturation was noticed (cf. Table 3). Respiratory rate was unchanged but respiratory amplitude augmented significantly during the ICP rise (cf. Table 3). Spectral analysis of HR variability (cf. Table 4) showed that the rise in ICP was significantly associated with a decrease in HF power (parasympathetic index), whereas LF power and LF/HF ratio increased. This pattern of vagal withdrawal is in accordance with the MSNA results. As in mice, in patients a modest ICP increase augments pari passu efferent SNS outflow, and an ICP drop reduces SNS outflow.

![FIGURE 2](example-image-url) Example of a mouse recording with raw signals of ICP, respiration, ABP and sympathetic activity during modest ICP rise. Example of a mouse raw signal of ICP, respiration, ABP and neurogram of RSNA at baseline ICP (≈ 10 mmHg), ICP (≈ 20 mmHg) and plateau ICP (≈ 30 mmHg).
DISSCUSSION

Using direct gold-standard measurement of sympathetic activity, we demonstrate for the first time in animal and human that ICP is a reversible determinant of efferent sympathetic outflow, even at relatively low ICP levels. Mice and patients results are alike. ICP is a biophysical stress related to the forces within the brain. But ICP has also to be considered as a physiological stressor, driving sympathetic activity. Our data suggest a new neuronal control positively and reversibly linking ICP with sympathetic outflow. Our data point to a possible novel intracranial (i.e., central) baroreflex.

The Cushing response is an immensely powerful but agonal, terminal and irreversible event due to ischemia of the brainstem. It produces massive intrinsic (i.e., non-synaptic) activation of the sympatho-excitatory neurons of the ventrolateral medulla (Nagao et al., 1984). In that respect it is not regarded as a reflex but as a “last ditch” protection for an ischemic brain, analogous to the auto-resuscitative mechanism of gasping. We reproduce Harvey Cushing’s original experimental recording published in 1901. We display a sketch of the experimental setting in anesthetized dog (cf. Figure 8A) and an original recording (cf. Figures 8B,C). ICP augmentation close to ABP (cf. marker 1 in Figure 8C) results in an ABP rise and respiratory irregularities i.e., a Cushing response (cf. marker 2 in Figure 8C). Note the time delay between the ICP rise (marker 1) and the ABP response (marker 2). However, close analysis of the initial part

| TABLE 1 | Results of sympathetic activity and systemic parameters during modest ICP increase and decrease in animal (n = 15). |
|----------|--------------------------------------------------|
| ICP      | Baseline 10 mmHg 20 mmHg 30 mmHg Plateau Post infusion |
| ICP (mmHg) | 6.65 ± 0.67 11.72 ± 0.46 21.51 ± 0.43** | 30.96 ± 0.23** | 38.57 ± 1.02** | 9.14 ± 0.83†† |
| RSNA (bursts.s⁻¹) | 29.87 ± 4.00 32.29 ± 4.10 37.17 ± 4.69** | 43.36 ± 6.25** | 45.73 ± 6.42** | 34.82 ± 5.65† |
| ABPs (mmHg) | 94.21 ± 7.25 90.22 ± 7.35 92.06 ± 6.26 | 94.90 ± 6.24 | 97.52 ± 6.34 | 90.35 ± 6.54 |
| ABPd (mmHg) | 68.67 ± 6.19 65.72 ± 6.35 67.06 ± 5.39 | 69.17 ± 4.98 | 71.36 ± 4.76 | 67.84 ± 5.41 |
| HR (beats.min⁻¹) | 307.14 ± 17.59 | 311.51 ± 18.20 308.76 ± 17.00 | 321.47 ± 17.64 | 329.74 ± 16.43 | 356.57 ± 17.80** |
| Resp. rate (min⁻¹) | 113.94 ± 5.21 | 111.97 ± 7.44 | 114.66 ± 5.67 | 123.79 ± 5.89 | 122.52 ± 5.16 | 119.65 ± 5.93 |
| Resp. amplitude (%) | 100.0 ± 0.0 | 112.9 ± 9.6 | 128.6 ± 11.7* | 128.6 ± 9.6* | 128.1 ± 8.6* | 120.4 ± 8.7†† |

Intracranial pressure (ICP), renal sympathetic nerve activity (RSNA), systolic arterial blood pressure (ABPs), diastolic arterial blood pressure (ABPd), heart rate (HR), respiratory rate and respiratory amplitude were calculated in mice during 60s epochs at different ICP levels: 7 mmHg (baseline), 10 mmHg, 20 mmHg, 30 mmHg, 40 mmHg (plateau), and 9 mmHg (post infusion, i.e., 5 min after the end of the infusion). Data are depicted as mean ± sem. Statistical analysis was carried out using ANOVA. *p < 0.05, **p < 0.01 vs. baseline and †p < 0.05, ††p < 0.01 vs. plateau.
of this recording shows that a modest ICP increase from 0 to \( \approx 20 \) mmHg (cf. marker ③ in Figure 8C) yields immediate fluctuation of ABP and deep breath with increase in respiratory amplitude (cf. marker ④ in Figure 8C). Note the synchronicity between ICP rise (marker ③), ABP fluctuation and respiratory change (marker ④). This is in accordance with our experimental results in mice and patients. More than a century ago, Harvey Cushing was evidently recording sympathetic activation during modest ICP rise in dog. It seems that the Cushing response is the tip of an iceberg, very last hemodynamic consequence of a continuous sympathetic activation that parallels the ICP rise. Historical and modern literature suggest the presence of an intracranial (i.e., central) baro-sensitive mechanism regulating efferent sympathetic activity.
TABLE 3 | Results of sympathetic activity and systemic parameters during modest ICP increase and decrease in human (n = 10).

| ICP               | Baseline | 10 mmHg | 15 mmHg | 20 mmHg | Plateau | Post infusion |
|-------------------|----------|---------|---------|---------|---------|---------------|
| CSF Pressure (mmHg) | 8.28 ± 1.05 | 10.72 ± 0.40 | 15.64 ± 0.22 | 20.43 ± 0.31** | 25.05 ± 0.33** | 14.83 ± 0.91† |
| MSNA (bursts.min⁻¹) | 51.24 ± 2.52 | 53.85 ± 2.54 | 59.96 ± 2.96** | 66.50 ± 4.17** | 66.70 ± 2.88** | 58.85 ± 2.62†† |
| MSNA (bursts/100 HB) | 82.86 ± 3.16 | 88.04 ± 5.54 | 98.60 ± 5.47** | 107.50 ± 5.54** | 106.00 ± 6.57** | 96.23 ± 4.41** |
| ABPs (mmHg) | 145.89 ± 9.56 | 148.04 ± 9.96 | 149.64 ± 9.42 | 150.43 ± 9.97 | 153.28 ± 10.04 | 152.67 ± 10.67 |
| ABPd (mmHg) | 74.57 ± 3.83 | 75.36 ± 3.84 | 74.41 ± 3.84 | 74.41 ± 3.78 | 77.10 ± 3.18 | 77.79 ± 4.08 |
| HR (beats.min⁻¹) | 62.39 ± 3.54 | 62.44 ± 3.75 | 61.63 ± 3.30 | 62.37 ± 3.52 | 63.04 ± 3.66 | 63.44 ± 3.17 |
| Oxygen saturation (%) | 94.98 ± 1.03 | 94.96 ± 0.92 | 94.99 ± 0.96 | 94.96 ± 0.87 | 95.45 ± 0.87 | 95.85 ± 0.91 |
| Respiratory rate (min⁻¹) | 17.06 ± 1.02 | 17.10 ± 1.06 | 17.26 ± 1.13 | 17.18 ± 1.07 | 17.01 ± 1.11 | 17.36 ± 1.07 |
| Respiratory amplitude (%) | 100.0 ± 0.00 | 103.7 ± 1.4 | 118.2 ± 11.0 | 129.6 ± 12.4 | 133.6 ± 14.0* | 123.0 ± 12.7 |

TABLE 4 | Results of heart rate variability analysis during modest ICP increase in human (n = 10).

| ICP               | Baseline ICP | Plateau ICP |
|-------------------|--------------|-------------|
| CSF Pressure (mmHg) | 8.66 ± 0.97 | 25.41 ± 3.29** |
| HF (nu) | 23.59 ± 4.53 | 17.19 ± 3.81* |
| LF (nu) | 33.68 ± 3.29 | 40.87 ± 4.55* |
| LF/HF | 2.01 ± 0.30 | 3.48 ± 0.79** |

This table gives the results of HR variability analysis at baseline and during fluid challenge in patients; mean ± sem values of CSF pressure, high frequency power (HF), low frequency power (LF), and LF/HF ratio in normalized units. Significance values (ANOVA) are indicated vs. baseline *p < 0.05, **p < 0.01 vs. baseline and †p < 0.05, ††p < 0.01 vs. plateau.

We demonstrate in mice and patients that during ICP augmentation, both RSNA and MSNA increase prior to any significant ABP rise. In a previous study we analyzed changes in ABP during ICP rise in a larger group of similar patients (n = 34) but without MSNA measurement (Schmidt et al., 2005). In this latter study ICP increase (from 8.2 ± 0.9 to 25.0 ± 1.4 mmHg), had a statistically significant effect on both systolic ABP (145.3 ± 6.2 to 156.7 ± 6.4 mmHg) and diastolic ABP (76.5 ± 5.4 to 90.5 ± 4.5 mmHg). In our current group, we only identified a trend in ABP increase (cf. Table 3). In the present study, the reduced sample size (n = 10) probably explains the lack of power and the absence of statistical significance. We know from normotensive subjects with high levels of baseline MSNA that a relatively low value of cardiac output can offset the influence of higher sympathetic outflow and vascular resistance (Charkoudian et al., 2006). Therefore, the increase in MSNA or RSNA without substantial ABP rise suggests either a parallel opposing vasodilator mechanism or latency between SNS augmentation and systemic response.

ICP-mediated sympathetic activation may result either from a baro-sensitive or a chemo-sensitive mechanism. The baro-sensitive mechanism is supported by the presence of pressure-sensitive areas in the brainstem with ability to trigger a sympathetically-mediated systemic response (McBryde et al., 2017). In anesthetized dogs, direct solid stress on the surface of the brainstem without altering ICP produced an increase in ABP (Thompson and Malina, 1959). Pressure receptive area was more precisely identified in the lower brainstem (Hoff and Reis, 1970; Doba and Reis, 1972; Reis and Doba, 1972). A subpial catecholaminergic neuronal group was identified in the rostroventral medulla yielding a pressor response when stimulated mechanically (Dampney et al., 1982; Jannetta et al., 1985). In human autopsy series, a similar population of catecholaminergic neurons has been identified in the subpial regions of the retro-olivary sulcus (Aicher et al., 1996). The baro-sensitive mechanism hypothesis is also in line with the concept of “neurogenic” origin of hypertension (Jannetta et al., 1985) since mechanical compression of the lateral part of the medulla can play a role in ABP elevation (Reis and Doba, 1972). The ICP-mediated systemic response seems to be rapid, beginning within 1 s of the onset of direct intracranial compression (Rodbard (Dickinson, 1990; Paton et al., 2009; McBryde et al., 2017), but direct evidence was still lacking. Our data seem to show that sympathetic activity parallels ICP changes. We propose to summarize our hypothesis with a simple graph (cf. Figure 9).

From our data we propose a unified physiological concept that might correspond to an intracranial (i.e., central) baroreflex, but direct evidence was still lacking. Our data seem to show that sympathetic activity parallels ICP changes. We propose to summarize our hypothesis with a simple graph (cf. Figure 9). From our data we propose a unified physiological concept that might correspond to an intracranial (i.e., central) baroreflex, with possible implication in the regulation of sympathetic activity set-point. Indeed SNS plays a significant role in ABP short-term regulation, mainly by extracranial (i.e., peripheral) baroreflex mechanisms (Cowley et al., 1973) but also by complex homeostatic feedback mechanisms (Dampney et al., 2002). In contrast to the sympathetic-inhibitor extracranial baroreflex, this novel intracranial baroreflex seems to be sympatho-activator. Hence, intracranial and extracranial baroreflex might act in opposition on the SNS. The former activates but the latter inhibits the sympathetic activity, as a fine-tuning regulatory mechanism of SNS. This represents a paradigm shift in the physiology of heart/brain regulatory cross-talk with novel insight into the pathophysiology of cardio-metabolic homeostasis imbalance. The paradoxical decrease in cardiac baroreflex sensitivity due to vagal modulation in the upright posture (Silvani et al., 2017) or the alteration of cerebral autoregulation in subjects prone to syncope (Bari et al., 2017) might be in line with our hypothesis.
FIGURE 8 | (A) Sketch of the original experimental setting from Cushing (1901). A needle was inserted in the cisterna magna of a dog to measure the CSF pressure assumed to be the pressure in the brain (Hirndruck). The needle connected via a tube to a bottle filled with warm saline (physiologische Kochsalzlösung). ABP was (Continued)
yielded a simultaneous increase in breath depth (cf. marker ③ in Figure 8C). This is in accordance with our animal and human data. Breathing is a motor behavior, generated and controlled by the central nervous system. Breathing fluctuates with sympathetic activity (Dempsey et al., 2002; Jäning and Hӓbler, 2003). Neurons that generate breathing are arranged in the lateral pons (Alheid et al., 2004) and extend to the rostral ventrolateral medulla (Dutschmann and Dick, 2012). Baro-sensitive neurons that regulate sympathetic effference also extend to the rostral ventrolateral medulla and are strongly inhibited by activation of peripheral (i.e., extracranial) arterial baroreceptors and higher centers in the brain (Dampney et al., 2002; Guyenet, 2006). Hence the rostral ventrolateral medulla seems to be a nodal point for ABP and respiration regulation. Previous work already suggested that peripheral chemoreflex and baroreflex share common interconnecting pathways (Despas et al., 2012). Our data support the concept of a central cardiorespiratory integration network.

Sympathetic activity is responsible for priming the body for action, particularly in stress situations threatening survival. Sympathetic over-activity is associated with the initiation, progression and prognosis of various disorders like arterial hypertension, heart and renal failure, diabetes mellitus or obesity (Grassi et al., 2007). In patients, we show that a modest 7 mmHg ICP rise (from 8 to 15 mmHg) significantly increases sympathetic activity by 17% (from 51.2 to 60 bursts.min−1) without ABP change (cf. Table 3). A 7 mmHg ICP increase occurs very frequently in everyday life of healthy individuals, for example when lying down from the upright to the horizontal position (Magnaes, 1976). Our hypothesis is also supported by the demonstration that acute head down tilt test is associated with an enlargement of the optic nerve sheath diameter reflecting ICP rise, and an increase in sympathetic activity using MSNA recording (Kermorgan et al., under review). Similar or higher ICP increases are encountered in various pathological conditions such as head trauma, hydrocephalus, stroke and airway obstruction with sleep apnoea (Rangel-Castilla et al., 2008). After a stroke, sympathetic over-activity is reported with increased risk of cardiovascular complications and poor outcome (Hilz et al., 2011). Takotsubo cardiomyopathy, an acute heart failure attributed to a surge in catecholamine levels, is reported after intracranial hemorrhage with intracranial hypertension (Abd et al., 2014). Obesity and weight gain, that represent major risk factors for obstructive sleep apnoea, are also associated with ABP and MSNA increases (Narkiewicz et al., 1998). In those acute or chronic conditions, the exact role of modest ICP rise on sympathetic overdrive has to be addressed.

and Stone, 1955). The absence of latency between intracranial stress and sympathetic response also supports the hypothesis of an intracranial baro-sensitivity, since ischaemia/anoxia would take longer to develop (cf. marker ③ and ④ in Figure 8C). The chemo-sensitive hypothesis stipulates that hypoxia increases sympathetic tone. The key organs for monitoring the delivery of oxygen to the brain are the extra cranial carotid bodies that are not directly influenced by ICP. The sympathetic adjustments triggered by acute mild hypoxia are initiated by activation of peripheral chemoreceptors whereas more severe hypoxia activates the sympathetic outflow via direct effects on the brainstem (Bruce and Cherniack, 1987; Guyenet, 2000). The rapid and reversible ICP-mediated sympathetic activation in awake patients probably points to a mechanic (baro-sensitive) rather than hypoxic (chemo-sensitive) central mechanism. However, the exact mechanism by which ICP modulates sympathetic circuit within the brain stem requires further studies.

We show in mice and patients a parallel increase in ICP, sympathetic activity and respiration amplitude. An ICP drop was also associated with a parallel decrease in sympathetic activity and respiration amplitude (cf. Tables 1, 3). From the Cushing experiment, a modest and rapid increase in ICP
There are several limitations to our study. First, the size of the study populations is rather small. However, we used RSNA and MSNA as the main criteria to assess SNS activity and these parameters have a reduced intra-individual variability making them suitable for such limited population size. Second, included patients were not normal subjects but patients suspected of hydrocephalus. Even though confirmation in normal volunteers is necessary to demonstrate that an intracranial baroreflex is part of normal physiology, for ethical reasons it was more appropriate at this stage to carry out this first study in patients. Third, although our data demonstrate that ICP regulates efferent SNS drive, additional work is necessary to identify the afferent SNS activation pathways and the intracranial baroreceptor underlying SNS modulation. Finally, it is necessary to investigate the time-course and persistence of this novel highly-regulated SNS modulatory circuit, as well as its relevance in terms of clinical practice.

In line with the composite nature of baroreflex (Marchi et al., 2016b; Reyes Del Paso et al., 2017) our data pave the way for further work in order to (i) investigate ICP as a new arm of baroreflex, (ii) validate the hypothesis of an intracranial baroreflex, (iii) identify the afferent pathway and the cardiorespiratory integration centers, (iv) demonstrate that ICP modulates sympathetic activity set-point, (v) investigate the role of raised ICP in the pathogenesis of sympathetic overactivity, (vi) explore the possible sympatholytic effect of reducing ICP, and finally (vii) determine whether ICP control, e.g., with a drug or a ventricular shunt, should be clinically relevant in sympathetically-driven diseases.

ETHICS STATEMENT

The animal study was approved by the University of Iowa Animal Research Committee. The human study was approved by the competent authority (N° ANSM 2007-A01430-53), by local Ethics committee (N° 2008-0044) and registered on ClinicalTrials.gov under n° NCT01776801. Patients gave their written consent for participation to the study.

AUTHOR CONTRIBUTIONS

The animal experiments have been done in the Departments of Pharmacology, University of Iowa, Iowa City, Iowa, USA. The human study has been performed in the Autonomic Unit of the University Hospital of Toulouse, Toulouse, France. ES was PI of the study. He conceived and designed the project, included the patients in the study, acquired mouse and human data. He was the main writer of the paper. FD was involved in acquisition and analysis of the microneurography in mice and human. He did the statistical analysis and revised the paper. AP-LT was responsible for acquisition and analysis of the heart rate variability. She also revised the paper. ZC and JP were important intellectual collaborators. They conceived the concept of the work and thoroughly revised the paper. KR supervised the animal work and revised the paper. AP was involved in the acquisition of microneurography in human, and designed the animal study. He revised the paper. JS was responsible for the draft, critical approach and intellectual content of the work. He revised the manuscript in details. All authors approved the final version of the manuscript and agree to be accountable for the accuracy or integrity of any part of the work. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

FUNDING

This work was supported by a grant from the CESNA (Club d’Etude du Système Nerveux Autonome) and promoted by University Hospital of Toulouse. JP was supported by an NIHR Senior Investigator Award, the Cambridge University Hospitals NIHR Biomedical Research Centre. ZC is supported by MRC Program Grants. KR is supported by the US National Institutes of Health (HL084207), the American Heart Association (Award #14EIA18860041), the University of Iowa Fraternal Order of Eagles Diabetes Research Center, and the University of Iowa Center for Hypertension Research.

ACKNOWLEDGMENTS

We express our gratitude to Donald A. Morgan from Iowa University for his skilled technical assistance for the mouse studies and to Julian R. Paton for fruitful discussion about the Cushing response. We specially thank Marine Lebrin for her technical support. And welcome to Celeste.

REFERENCES

Abd, T. T., Hayek, S., Cheng, J. W., Samuels, O. B., Wittstein, I. S., and Lerakis, S. (2014). Incidence and clinical characteristics of takotsubo cardiomyopathy post-aneurysmal subarachnoid hemorrhage. Int. J. Cardiol. 176, 1362–1364. doi: 10.1016/j.ijcard.2014.07.279
Aicher, S. A., Saravay, R. H., Cravo, S., Jeske, I., Morrison, S. F., Reis, D. J., et al. (1996). Monosynaptic projections from the nucleus tractus solitarii to C1 adrenergic neurons in the rostral ventrolateral medulla: comparison with input from the caudal ventrolateral medulla. J. Comp. Neurol. 373, 62–75. doi: 10.1002/sjc.1096-9861(19960909)373:1<62::AID-CNE6>3.0.CO;2-B
Alheid, G. F., Milsom, W. K., and McCrimmon, D. R. (2004). Pontine influences on breathing: an overview. Respir. Physiol. Neurobiol. 143, 105–114. doi: 10.1016/j.resp.2004.06.016
Bari, V., De Maria, B., Mazzucco, C. E., Rossato, G., Tonon, D., Nollo, G., et al. (2017). Cerebrovascular and cardiovascular variability interactions investigated through conditional joint transfer entropy in subjects prone to postural syncope. Physiol. Meas. 38, 976–991. doi: 10.1088/1361-6579/aa638c
Bruce, E. N., and Cherniack, N. S. (1987). Central chemoreceptors. J. Appl. Physiol. 62, 389–402. doi: 10.1152/jappl.1987.62.2.389
Charkoudian, N., Joyner, M. J., Sokolnicki, L. A., Johnson, C. P., Eisenach, J. H., Dietz, N. M., et al. (2006). Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. J. Physiol. 572, 821–827. doi: 10.1113/jphysiol.2005.104075
Cowley, A. W. Jr., Liard, J. F., and Guyton, A. C. (1973). Role of the baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. *Circ. Res.* 32, 564–576. doi: 10.1161/01.RES.32.5.564

Cushing, H. (1901). Concerning a definite regulatory mechanism of vasomotor centre which controls blood pressure during cerebral compression. *Bull. Johns Hopkins Hosp.* 12, 290–292.

Dampney, R. A., Coleman, M. J., Fontes, M. A., Hirooka, Y., Horiiuchi, J., Li, Y. W., et al. (2002). Central mechanisms underlying short- and long-term regulation of the cardiovascular system. *Clin. Exp. Pharmacol. Physiol.* 29, 261–268. doi: 10.1046/j.1440-1681.2002.03640.x

Dampney, R. A., Goodchild, A. K., Robertson, L. G., and Montgomery, W. (1982). Role of ventrolateral medulla in vasomotor regulation: a correlative anatomical and physiological study. *Brain Res.* 249, 223–235. doi: 10.1016/0006-8993(82)90057-6

Dempsey, J. A., Sheel, A. W., St Croix, C. M., and Morgan, B. J. (2002). Respiratory influences on sympathetic vasomotor outflow in humans. *Respir. Physiol. Neurobiol.* 130, 3–20. doi: 10.1016/S0303-6487(01)00327-9

Despas, F., Lambert, E., Vaccaro, A., Labrunee, M., Franchitto, N., Lebrin, M., et al. (2012). Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. *J. Hypertens.* 30, 753–760. doi: 10.1097/HJH.0b013e328351386c

Dickinson, C. J. (1981). Neurogenic hypertension revisited. *Clin. Sci.* 60, 471–477. doi: 10.1042/cs0600471

Dickinson, C. J. (1990). Reappraisal of the Cushing reflex: the most powerful neural blood pressure stabilizing system. *Clin. Sci.* 79, 543–550. doi: 10.1042/cs0790543

Dickinson, C. J., and McCubbin, J. W. (1963). Pressor effect of increased cerebrospinal fluid pressure and vertebral artery occlusion with and without anesthesia. *Circ. Res.* 12, 190–202. doi: 10.1161/01.RES.12.2.190

Doba, N., and Reis, D. I. (1972). Localization within the lower brainstem of a receptive area mediating the pressor response to increased intracranial pressure. (The Cushing response). *Brain Res.* 47, 487–491. doi: 10.1016/0006-8993(72)90655-5

Donnelly, J., Czosnyka, M., Harland, S., Varsos, G. V., Cardim, D., Robba, C., et al. (2017). Cerebral haemodynamics during experimental intracranial hypertension. *J. Cereb. Blood Flow Metab.* 37, 694–705. doi: 10.1177/0271678X16639060

Dutschmann, M., and Dick, T. E. (2012). Pontine mechanisms of respiratory control. *Compr. Physiol.* 2, 2443–2469. doi: 10.1002/cphy.c100015

Edvinsson, L., Owman, C., and West, K. A. (1971). Modification of kaolin-induced intracranial hypertension at various time-periods after superior cerebellar artery compression. *Acta Physiol. Scand.* 83, 51–59. doi: 10.1111/j.1460-2986.1971.tb00505.x

Fitch, W., McDowell, D. G., Paterson, G. M., and Hain, W. R. (1977). Systemic vascular responses to increased intracranial pressure. 3. Effects of individual balloon inflations on intracranial pressure and the systemic effects. *J. Neurosurg. Neuropsychiat.* 41, 340–344. doi: 10.1136/jnp.41.4.340

Grassi, G., Seravalle, G., Quarti-Trevano, F., Scopelliti, F., Dell’Oro, R., Bolla, G., et al. (2016). Calibrated variability of muscle sympathetic nerve activity during graded head-up tilt in humans and its link with noradrenaline data and cardiovascular rhythms. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 310, 1134–1143. doi: 10.1152/ajpregu.00541.2015

Marchi, A., Bari, V., De Maria, B., Eder, M., Lamberti, E., Baumert, M., et al. (2016). Simultaneous characterization of sympathetic and cardiac arms of the baroreflex through sequence techniques during incremental Head-Up Tilt. *Front. Physiol.* 7:348. doi: 10.3389/fphys.2016.00348

Marmarou, A., Bergsneider, M., Klinge, P., Relkin, N., and Black, P. M. (2005). Acute intracranial hypertension and brain-stem blood flow. An experimental study. *J. Neurosurg.* 60, 566–571. doi: 10.1017/s0162037105008201

McBride, F. D., Malpas, S. C., and Paton, J. F. (2017). Intracranial mechanisms for preserving brain blood flow in health and disease. *Acta Physiol. (Oxf)* 209, 274–287. doi: 10.1111/apha.12706

McGillivray, J. E., Kindt, G. W., and Raisis, J. E., Miller, C. A. (1978). The relation of cerebral ischemia, hypoxia, and hypercarbia to the Cushing response. *J. Neurosurg.* 48, 730–740. doi: 10.3171/jns.1978.48.5.0730

Nagao, S., Sunami, N., Tsutsui, T., Honma, Y., Momma, F., Nishiura, T., et al. (1982). Body position and cerebrospinal fluid pressure. Part 2: Clinical studies on orthostatic pressure and the hydrostatic indifferent point. *J. Neurosurg.* 56, 290–292. doi: 10.3181/00379727-37-9531

Narkiewicz, K., van de Borne, P. J., Cooley, R. L., Dyken, M. E., and Somers, V. K. (1998). Sympathetic activity in obese subjects with and without obstructive sleep apnea. *Circulation* 98, 772–776. doi: 10.1161/01.CIR.98.8.772

Narins, P. G., (2006). Neural structures that mediate sympathoexcitatory activity during hypoxia. *Respir. Physiol.* 121, 147–162. doi: 10.1016/j.resp.2005.02.015

Niccoli, J. F., and Guyton, A. C. (1973). Regulation of the baroreflex through sequence techniques during incremental Head-Up Tilt. *Clin. Sci.* 43, 753–760. doi: 10.1111/j.1442-2410.1973.tb02463.x

Niccoli, J. F., and Guyton, A. C. (1973). Regulation of the baroreflex through sequence techniques during incremental Head-Up Tilt. *Neurology* 33, 51–59. doi: 10.1212/wnl.33.1.51

N. Engl. J. Med. 327, 564–580. doi: 10.1056/NEJM19721228287261

Reyes Del Paso, G. A., de la Coba, P., Martinez-Vazquez, M., and Thayer, J. F. (2017). Time domain measurement of the vascular and myocardin branches of the baroreflex: a study in physically active versus sedentary individuals. *Psychophysiology* 54, 1528–1540. doi: 10.1111/psyp.12989

Rodbard, S., and Stone, W. (1955). Pressor mechanisms induced by intracranial compression. *Circulation* 12, 883–890. doi: 10.1161/01.CIR.12.5.883
Schmidt et al. Intracranial Baroreflex

Santamarta, D., Abásolo, D., Martínez-Madrigal, M., and Hornero, R. (2012). Characterisation of the intracranial pressure waveform during infusion studies by means of central tendency measure. Acta Neurochir. 154, 595–602. doi: 10.1007/s00701-012-1441-y

Schmidt, E. A., Czosnyka, Z., Momjian, S., Czosnyka, M., Bech, R. A., and Pickard, J. D. (2005). Intracranial baroreflex yielding an early Cushing response in human. Acta Neurochir. Suppl. 95, 253–256. doi: 10.1007/3-211-32318-X_51

Silvani, A., Calandra-Buonaura, G., Blair, D., Johnson, B. D., van Helmond, N., Barletta, G., Cecere, A. G. (2017). Physiological mechanisms mediating the coupling between heart period and arterial pressure in response to postural changes in humans. Front. Physiol. 8:163. doi: 10.3389/fphys.2017.00163

Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (1996). Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 93, 1043–1065. doi: 10.1161/01.CIR.93.5.1043

Thompson, R. K., and Malina, S. (1959). Dynamic axial brainstem distortion as a mechanism explaining the cardiorespiratory changes in increased intracranial pressure. J. Neurosurg. 16, 664–675. doi: 10.3171/jns.1959.16.6.0664

Van Loon, J., Shivalkar, B., Plets, C., Goffin, J., Tjandra-Maga, T. B., and Flameng, W. (1993). Catecholamine response to a gradual increase of intracranial pressure. J. Neurosurg. 79, 705–709. doi: 10.3171/jns.1993.79.5.0705

White, D. H., Shoemaker, J. K., and Raven, R. B. (2015). Sympathetic nervous system and blood pressure in humans. Individualized patterns of regulation and their implications. Auton. Neurosci. 193, 12–21. doi: 10.1016/j.autneu.2015.08.004

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Schmidt, Despas, Pavy-Le Traon, Czosnyka, Pickard, Rahmouni, Pathak and Senard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.